Advertisement
Screener

Opus Genetics, Inc. (IRD) Research and Development Expense

2.8 / 5 stars · 68/120 Roast Me

Opus Genetics, Inc. Research and Development Expense

Opus Genetics, Inc. (IRD) reported Research and Development Expense of $149.59 thousand for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-10-29.

Discontinued › Expense Statement › Operating Expenses

us-gaap:ResearchAndDevelopmentExpense · last filed 2020-10-29

  • Opus Genetics, Inc. research and development expense for the quarter ending 2020-09-30 was $149.59K, a 86.78% decline year-over-year.
  • Opus Genetics, Inc. research and development expense for the quarter ending 2020-06-30 was $231.61K, a 85.95% decline year-over-year.
  • Opus Genetics, Inc. research and development expense for the quarter ending 2020-03-31 was $456.79K, a 79.63% decline year-over-year.
  • Opus Genetics, Inc. research and development expense for the quarter ending 2019-12-31 was $454.73K, a 83.34% decline year-over-year.
  • Opus Genetics, Inc. research and development expense for fiscal 2019 was $5.48M, a 58.22% decline from fiscal 2018.
  • Opus Genetics, Inc. research and development expense for fiscal 2018 was $13.11M, a 22.34% increase from fiscal 2017.
  • Opus Genetics, Inc. research and development expense for fiscal 2017 was $10.72M, a 6.21% increase from fiscal 2016.
  • Opus Genetics, Inc. research and development expense for fiscal 2016 was $10.09M, a 16.95% decline from fiscal 2015.
Period endResearch and Development Expense 3 monthResearch and Development Expense 3 month as first filedResearch and Development Expense 6 monthResearch and Development Expense 6 month as first filedResearch and Development Expense 9 monthResearch and Development Expense 12 monthResearch and Development Expense 132 monthResearch and Development Expense 135 monthResearch and Development Expense 138 monthResearch and Development Expense 141 monthResearch and Development Expense 144 monthResearch and Development Expense 147 monthResearch and Development Expense 150 monthResearch and Development Expense 153 monthResearch and Development Expense 156 month
2020-09-30$149.59K
10-Q · filed 2020-10-29
$381.20K
derived: sum of 2 quarters · filed 2020-10-29
$837.99K
10-Q · filed 2020-10-29
$1.29M
derived: sum of 4 quarters · filed 2020-10-29
2020-06-30$231.61K
10-Q · filed 2020-08-14
$688.40K
10-Q · filed 2020-08-14
$1.14M
derived: sum of 3 quarters · filed 2020-08-14
$2.27M
derived: sum of 4 quarters · filed 2020-10-29
2020-03-31$456.79K
10-Q · filed 2020-05-07
$911.52K
derived: sum of 2 quarters · filed 2020-05-07
$2.04M
derived: sum of 3 quarters · filed 2020-10-29
$3.69M
derived: sum of 4 quarters · filed 2020-10-29
2019-12-31$454.73K
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21
$1.59M
derived: sum of 2 quarters · filed 2020-10-29
$3.23M
derived: sum of 3 quarters · filed 2020-10-29
$5.48M
10-K · filed 2020-02-21
2019-09-30$1.13M
10-Q · filed 2020-10-29
$2.78M
derived: sum of 2 quarters · filed 2020-10-29
$5.02M
10-Q · filed 2020-10-29
$7.75M
derived: sum of 4 quarters · filed 2020-10-29
2019-06-30$1.65M
10-Q · filed 2020-08-14
$3.89M
10-Q · filed 2020-08-14
$6.62M
derived: sum of 3 quarters · filed 2020-08-14
$9.51M
derived: sum of 4 quarters · filed 2020-08-14
2019-03-31$2.24M
10-Q · filed 2020-05-07
$4.97M
derived: sum of 2 quarters · filed 2020-05-07
$7.86M
derived: sum of 3 quarters · filed 2020-05-07
$11.29M
derived: sum of 4 quarters · filed 2020-05-07
2018-12-31$2.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21
$5.62M
derived: sum of 2 quarters · filed 2020-02-21
$9.05M
derived: sum of 3 quarters · filed 2020-02-21
$13.11M
10-K · filed 2020-02-21
2018-09-30$2.89M
10-Q · filed 2019-11-06
$6.32M
derived: sum of 2 quarters · filed 2019-11-06
$10.38M
10-Q · filed 2019-11-06
$13.64M
derived: sum of 4 quarters · filed 2019-11-06
2018-06-30$3.43M
10-Q · filed 2019-08-07
$7.49M
10-Q · filed 2019-08-07
$10.75M
derived: sum of 3 quarters · filed 2019-08-07
$13.40M
derived: sum of 4 quarters · filed 2019-08-07
2018-03-31$4.06M
10-Q · filed 2019-05-10
$7.32M
derived: sum of 2 quarters · filed 2019-05-10
$9.97M
derived: sum of 3 quarters · filed 2019-05-10
$12.51M
derived: sum of 4 quarters · filed 2019-05-10
2017-12-31$3.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07
$5.91M
derived: sum of 2 quarters · filed 2019-03-07
$8.45M
derived: sum of 3 quarters · filed 2019-03-07
$10.72M
10-K · filed 2019-03-07
2017-09-30$2.64M
10-Q · filed 2018-11-02
$5.19M
derived: sum of 2 quarters · filed 2018-11-02
$7.45M
10-Q · filed 2018-11-02
$9.54M
derived: sum of 4 quarters · filed 2018-11-02
2017-06-30$2.54M
10-Q · filed 2018-08-03
$4.81M
10-Q · filed 2018-08-03
$6.89M
derived: sum of 3 quarters · filed 2018-08-03
$9.19M
derived: sum of 4 quarters · filed 2018-08-03
2017-03-31$2.26M
10-Q · filed 2018-05-04
$4.35M
derived: sum of 2 quarters · filed 2018-05-04
$6.65M
derived: sum of 3 quarters · filed 2018-05-04
$8.88M
derived: sum of 4 quarters · filed 2018-05-04
2016-12-31$2.08M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09
$4.38M
derived: sum of 2 quarters · filed 2018-03-09
$6.62M
derived: sum of 3 quarters · filed 2018-03-09
$10.09M
10-K · filed 2018-03-09
2016-09-30$2.30M
10-Q · filed 2017-11-03
$4.54M
derived: sum of 2 quarters · filed 2017-11-03
$8.00M
10-Q · filed 2017-11-03
$10.92M
derived: sum of 4 quarters · filed 2018-03-09
2016-06-30$2.24M
10-Q · filed 2017-08-04
$5.71M
10-Q · filed 2017-08-04
$8.62M
derived: sum of 3 quarters · filed 2018-03-09
$11.73M
derived: sum of 4 quarters · filed 2018-03-09
2016-03-31$3.47M
10-Q · filed 2017-05-03
$6.38M
derived: sum of 2 quarters · filed 2018-03-09
$9.49M
derived: sum of 3 quarters · filed 2018-03-09
$12.72M
derived: sum of 4 quarters · filed 2018-03-09
2015-12-31$2.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09
$6.02M
derived: sum of 2 quarters · filed 2018-03-09
$9.26M
derived: sum of 3 quarters · filed 2018-03-09
$12.15M
10-K · filed 2018-03-09
2015-09-30$3.10M
10-Q · filed 2016-11-04
$6.34M
derived: sum of 2 quarters · filed 2016-11-04
$9.23M
10-Q · filed 2016-11-04
$11.45M
derived: sum of 4 quarters · filed 2017-02-24
2015-06-30$3.24M
10-Q · filed 2016-08-05
$6.13M
10-Q · filed 2016-08-05
$8.35M
derived: sum of 3 quarters · filed 2017-02-24
$10.17M
derived: sum of 4 quarters · filed 2017-02-24
2015-03-31$2.89M
10-Q · filed 2016-05-06
$5.11M
derived: sum of 2 quarters · filed 2017-02-24
$6.94M
derived: sum of 3 quarters · filed 2017-02-24
$8.64M
derived: sum of 4 quarters · filed 2017-02-24
2014-12-31$2.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-24
$4.04M
derived: sum of 2 quarters · filed 2017-02-24
$5.74M
derived: sum of 3 quarters · filed 2017-02-24
$7.02M
10-K · filed 2017-02-24
2014-09-30$1.82M
10-Q · filed 2015-11-02
$3.53M
derived: sum of 2 quarters · filed 2015-11-02
$4.80M
10-Q · filed 2015-11-02
$5.79M
derived: sum of 4 quarters · filed 2016-03-14
2014-06-30$1.70M
10-Q · filed 2015-08-07
$2.97M
10-Q · filed 2015-08-07
$3.97M
derived: sum of 3 quarters · filed 2016-03-14
$4.75M
derived: sum of 4 quarters · filed 2016-03-14
2014-03-31$1.27M
10-Q · filed 2015-05-08
$2.27M
derived: sum of 2 quarters · filed 2016-03-14
$3.05M
derived: sum of 3 quarters · filed 2016-03-14
$3.97M
derived: sum of 4 quarters · filed 2016-03-14
$39.80M
10-Q · filed 2014-05-14
2013-12-31$994.26K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14
$1.78M
derived: sum of 2 quarters · filed 2016-03-14
$2.70M
derived: sum of 3 quarters · filed 2016-03-14
$3.25M
10-K · filed 2016-03-14
$38.53M
10-K · filed 2014-03-21
2013-09-30$781.28K
10-Q · filed 2014-11-12
$1.71M
derived: sum of 2 quarters · filed 2014-11-12
$2.26M
10-Q · filed 2014-11-12
$2.52M
derived: sum of 4 quarters · filed 2014-11-12
$37.54M
10-Q · filed 2013-11-13
2013-06-30$925.13K
10-Q · filed 2014-08-13
$1.48M
10-Q · filed 2014-08-13
$1.74M
derived: sum of 3 quarters · filed 2014-08-13
$2.81M
derived: sum of 4 quarters · filed 2014-08-13
$36.76M
10-Q · filed 2013-08-12
2013-03-31$552.47K
10-Q · filed 2014-05-14
$818.16K
derived: sum of 2 quarters · filed 2014-05-14
$1.88M
derived: sum of 3 quarters · filed 2014-05-14
$2.90M
derived: sum of 4 quarters · filed 2014-05-14
$35.83M
10-Q · filed 2013-05-09
2012-12-31$265.69K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-21
$1.33M
derived: sum of 2 quarters · filed 2014-03-21
$2.35M
derived: sum of 3 quarters · filed 2014-03-21
$3.39M
10-K · filed 2014-03-21
$35.28M
10-K · filed 2013-03-22
2012-09-30$1.07M
10-Q · filed 2013-11-13
$2.08M
derived: sum of 2 quarters · filed 2013-11-13
$3.13M
10-Q · filed 2013-11-13
$4.61M
derived: sum of 4 quarters · filed 2013-11-13
$35.01M
10-Q · filed 2012-11-08
2012-06-30$1.02M
10-Q · filed 2013-08-12
$2.06M
10-Q · filed 2013-08-12
$3.55M
derived: sum of 3 quarters · filed 2013-08-12
$5.92M
derived: sum of 4 quarters · filed 2013-08-12
$33.95M
10-Q · filed 2012-08-08
2012-03-31$1.04M
10-Q · filed 2013-05-09
$2.53M
derived: sum of 2 quarters · filed 2013-05-09
$4.90M
derived: sum of 3 quarters · filed 2013-05-09
$10.32M
derived: sum of 4 quarters · filed 2013-05-09
$32.93M
10-Q · filed 2012-05-09
2011-12-31$1.49M
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-22
$3.86M
derived: sum of 2 quarters · filed 2013-03-22
$9.27M
derived: sum of 3 quarters · filed 2013-03-22
$11.99M
10-K · filed 2013-03-22
2011-09-30$2.37M
10-Q · filed 2012-11-08
$7.79M
derived: sum of 2 quarters · filed 2012-11-08
$10.51M
10-Q · filed 2012-11-08
$11.99M
derived: sum of 4 quarters · filed 2012-11-08
2011-06-30$5.42M
10-Q · filed 2012-08-08
$5.44M
10-Q · filed 2011-08-09
$8.13M
10-Q · filed 2012-08-08
$8.17M
10-Q · filed 2011-08-09
$9.62M
derived: sum of 3 quarters · filed 2012-08-08
$10.29M
derived: sum of 4 quarters · filed 2012-08-08
2011-03-31$2.72M
10-Q · filed 2012-05-09
$4.20M
derived: sum of 2 quarters · filed 2012-05-09
$4.87M
derived: sum of 3 quarters · filed 2012-05-09
$6.20M
derived: sum of 4 quarters · filed 2012-05-09
2010-12-31$1.48M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-16
$2.15M
derived: sum of 2 quarters · filed 2012-03-16
$3.48M
derived: sum of 3 quarters · filed 2012-03-16
$3.93M
10-K · filed 2012-03-16
2010-09-30$671.34K
10-Q · filed 2011-11-09
$2.00M
derived: sum of 2 quarters · filed 2011-11-09
$2.45M
10-Q · filed 2011-11-09
2010-06-30$1.33M
10-Q · filed 2011-08-09
$1.82M
10-Q · filed 2011-08-09
2009-12-31$3.18M
10-K · filed 2012-03-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
Turn Therapeutics Inc. (TTRX)United States$0.397B-25.68
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
Rezolute, Inc. (RZLT)United States$0.382B-6.45
CYPHERPUNK TECHNOLOGIES INC. (CYPH)United States$0.438B-75.63